nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—ADRA2A—type 2 diabetes mellitus	0.0991	0.325	CbGaD
Ziprasidone—HTR2C—type 2 diabetes mellitus	0.0912	0.299	CbGaD
Ziprasidone—CYP1A2—type 2 diabetes mellitus	0.0688	0.226	CbGaD
Ziprasidone—CYP3A4—type 2 diabetes mellitus	0.0456	0.15	CbGaD
Ziprasidone—DRD5—Bromocriptine—type 2 diabetes mellitus	0.0357	0.0851	CbGbCtD
Ziprasidone—HTR7—Bromocriptine—type 2 diabetes mellitus	0.0262	0.0624	CbGbCtD
Ziprasidone—DRD4—Bromocriptine—type 2 diabetes mellitus	0.0255	0.0607	CbGbCtD
Ziprasidone—HTR6—Bromocriptine—type 2 diabetes mellitus	0.023	0.0547	CbGbCtD
Ziprasidone—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0209	0.0499	CbGbCtD
Ziprasidone—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0201	0.0479	CbGbCtD
Ziprasidone—DRD3—Bromocriptine—type 2 diabetes mellitus	0.0189	0.0451	CbGbCtD
Ziprasidone—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.0182	0.0435	CbGbCtD
Ziprasidone—DRD1—Bromocriptine—type 2 diabetes mellitus	0.0182	0.0435	CbGbCtD
Ziprasidone—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0173	0.0412	CbGbCtD
Ziprasidone—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0146	0.0349	CbGbCtD
Ziprasidone—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0133	0.0318	CbGbCtD
Ziprasidone—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0126	0.03	CbGbCtD
Ziprasidone—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.012	0.0287	CbGbCtD
Ziprasidone—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.012	0.0287	CbGbCtD
Ziprasidone—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0115	0.0275	CbGbCtD
Ziprasidone—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0111	0.0264	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.00959	0.0229	CbGbCtD
Ziprasidone—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.00959	0.0229	CbGbCtD
Ziprasidone—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0072	0.0172	CbGbCtD
Ziprasidone—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00652	0.0156	CbGbCtD
Ziprasidone—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00582	0.0139	CbGbCtD
Ziprasidone—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00575	0.0137	CbGbCtD
Ziprasidone—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00537	0.0128	CbGbCtD
Ziprasidone—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00513	0.0122	CbGbCtD
Ziprasidone—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00512	0.0122	CbGbCtD
Ziprasidone—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00486	0.0116	CbGbCtD
Ziprasidone—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00468	0.0112	CbGbCtD
Ziprasidone—CYP3A5—Losartan—type 2 diabetes mellitus	0.00445	0.0106	CbGbCtD
Ziprasidone—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00441	0.0105	CbGbCtD
Ziprasidone—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00423	0.0101	CbGbCtD
Ziprasidone—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00409	0.00976	CbGbCtD
Ziprasidone—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0037	0.00883	CbGbCtD
Ziprasidone—CYP1A2—Losartan—type 2 diabetes mellitus	0.00331	0.00789	CbGbCtD
Ziprasidone—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00281	0.00669	CbGbCtD
Ziprasidone—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00269	0.00641	CbGbCtD
Ziprasidone—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00269	0.00641	CbGbCtD
Ziprasidone—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00254	0.00607	CbGbCtD
Ziprasidone—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0019	0.00452	CbGbCtD
Ziprasidone—HTR7—sympathetic nervous system—type 2 diabetes mellitus	0.00175	0.0568	CbGeAlD
Ziprasidone—CYP3A4—Losartan—type 2 diabetes mellitus	0.00173	0.00413	CbGbCtD
Ziprasidone—HTR2A—arteriole—type 2 diabetes mellitus	0.00171	0.0556	CbGeAlD
Ziprasidone—HTR7—autonomic nervous system—type 2 diabetes mellitus	0.00118	0.0382	CbGeAlD
Ziprasidone—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00109	0.0354	CbGeAlD
Ziprasidone—DRD1—nerve—type 2 diabetes mellitus	0.00106	0.0344	CbGeAlD
Ziprasidone—HTR3A—nerve—type 2 diabetes mellitus	0.00102	0.0332	CbGeAlD
Ziprasidone—Lurasidone—ADRA2A—type 2 diabetes mellitus	0.000905	0.325	CrCbGaD
Ziprasidone—HTR1B—artery—type 2 diabetes mellitus	0.000866	0.0281	CbGeAlD
Ziprasidone—HTR7—peripheral nervous system—type 2 diabetes mellitus	0.000849	0.0275	CbGeAlD
Ziprasidone—HTR1D—artery—type 2 diabetes mellitus	0.000838	0.0272	CbGeAlD
Ziprasidone—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000734	0.0238	CbGeAlD
Ziprasidone—HTR2A—hindlimb—type 2 diabetes mellitus	0.000679	0.022	CbGeAlD
Ziprasidone—HTR7—artery—type 2 diabetes mellitus	0.000667	0.0216	CbGeAlD
Ziprasidone—HTR7—nerve—type 2 diabetes mellitus	0.000662	0.0215	CbGeAlD
Ziprasidone—DRD2—nerve—type 2 diabetes mellitus	0.000626	0.0203	CbGeAlD
Ziprasidone—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000623	0.0202	CbGeAlD
Ziprasidone—HTR7—endothelium—type 2 diabetes mellitus	0.000564	0.0183	CbGeAlD
Ziprasidone—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.00053	0.0172	CbGeAlD
Ziprasidone—H1F0—islet of Langerhans—type 2 diabetes mellitus	0.00052	0.0169	CbGeAlD
Ziprasidone—HTR3A—islet of Langerhans—type 2 diabetes mellitus	0.000496	0.0161	CbGeAlD
Ziprasidone—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.00048	0.0156	CbGeAlD
Ziprasidone—H1F0—retina—type 2 diabetes mellitus	0.000444	0.0144	CbGeAlD
Ziprasidone—H1F0—nephron tubule—type 2 diabetes mellitus	0.000419	0.0136	CbGeAlD
Ziprasidone—HTR2A—artery—type 2 diabetes mellitus	0.000416	0.0135	CbGeAlD
Ziprasidone—Lurasidone—CYP3A4—type 2 diabetes mellitus	0.000416	0.149	CrCbGaD
Ziprasidone—HTR2A—nerve—type 2 diabetes mellitus	0.000413	0.0134	CbGeAlD
Ziprasidone—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000411	0.0133	CbGeAlD
Ziprasidone—ADRA1B—kidney—type 2 diabetes mellitus	0.00039	0.0126	CbGeAlD
Ziprasidone—H1F0—cardiovascular system—type 2 diabetes mellitus	0.000376	0.0122	CbGeAlD
Ziprasidone—H1F0—kidney—type 2 diabetes mellitus	0.000368	0.0119	CbGeAlD
Ziprasidone—H1F0—pancreas—type 2 diabetes mellitus	0.000365	0.0118	CbGeAlD
Ziprasidone—H1F0—cortex of kidney—type 2 diabetes mellitus	0.000358	0.0116	CbGeAlD
Ziprasidone—HTR2A—endothelium—type 2 diabetes mellitus	0.000352	0.0114	CbGeAlD
Ziprasidone—H1F0—adipose tissue—type 2 diabetes mellitus	0.000331	0.0107	CbGeAlD
Ziprasidone—CYP3A7—liver—type 2 diabetes mellitus	0.000314	0.0102	CbGeAlD
Ziprasidone—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000301	0.00975	CbGeAlD
Ziprasidone—CHRM2—cardiovascular system—type 2 diabetes mellitus	0.000299	0.0097	CbGeAlD
Ziprasidone—KCNH2—islet of Langerhans—type 2 diabetes mellitus	0.000299	0.00969	CbGeAlD
Ziprasidone—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000291	0.00944	CbGeAlD
Ziprasidone—HTR1D—kidney—type 2 diabetes mellitus	0.000285	0.00924	CbGeAlD
Ziprasidone—CHRM1—cardiovascular system—type 2 diabetes mellitus	0.000272	0.00883	CbGeAlD
Ziprasidone—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	0.000267	0.00864	CbGeAlD
Ziprasidone—DRD2—retina—type 2 diabetes mellitus	0.000259	0.00841	CbGeAlD
Ziprasidone—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000247	0.008	CbGeAlD
Ziprasidone—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000243	0.00787	CbGeAlD
Ziprasidone—CHRM3—kidney—type 2 diabetes mellitus	0.000238	0.00773	CbGeAlD
Ziprasidone—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000237	0.0077	CbGeAlD
Ziprasidone—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000235	0.00763	CbGeAlD
Ziprasidone—H1F0—liver—type 2 diabetes mellitus	0.000232	0.00754	CbGeAlD
Ziprasidone—HTR7—cardiovascular system—type 2 diabetes mellitus	0.000232	0.00752	CbGeAlD
Ziprasidone—HTR7—kidney—type 2 diabetes mellitus	0.000227	0.00736	CbGeAlD
Ziprasidone—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000224	0.00725	CbGeAlD
Ziprasidone—KCNH2—cardiovascular system—type 2 diabetes mellitus	0.000216	0.00701	CbGeAlD
Ziprasidone—Aripiprazole—ADRA2A—type 2 diabetes mellitus	0.000216	0.0774	CrCbGaD
Ziprasidone—CHRM3—adipose tissue—type 2 diabetes mellitus	0.000215	0.00697	CbGeAlD
Ziprasidone—Trazodone—ADRA2A—type 2 diabetes mellitus	0.000215	0.0771	CrCbGaD
Ziprasidone—ADRA2C—kidney—type 2 diabetes mellitus	0.000209	0.00676	CbGeAlD
Ziprasidone—ADRA2C—pancreas—type 2 diabetes mellitus	0.000207	0.00672	CbGeAlD
Ziprasidone—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000203	0.00659	CbGeAlD
Ziprasidone—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000199	0.00644	CbGeAlD
Ziprasidone—Aripiprazole—HTR2C—type 2 diabetes mellitus	0.000199	0.0713	CrCbGaD
Ziprasidone—Trazodone—HTR2C—type 2 diabetes mellitus	0.000198	0.0709	CrCbGaD
Ziprasidone—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000197	0.0064	CbGeAlD
Ziprasidone—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000188	0.0061	CbGeAlD
Ziprasidone—CYP3A5—kidney—type 2 diabetes mellitus	0.000175	0.00566	CbGeAlD
Ziprasidone—CYP3A5—pancreas—type 2 diabetes mellitus	0.000173	0.00562	CbGeAlD
Ziprasidone—HTR2A—retina—type 2 diabetes mellitus	0.000171	0.00554	CbGeAlD
Ziprasidone—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.00017	0.00551	CbGeAlD
Ziprasidone—ADRA2A—pancreas—type 2 diabetes mellitus	0.000165	0.00536	CbGeAlD
Ziprasidone—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000162	0.00526	CbGeAlD
Ziprasidone—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000157	0.0051	CbGeAlD
Ziprasidone—HRH1—adipose tissue—type 2 diabetes mellitus	0.000153	0.00495	CbGeAlD
Ziprasidone—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.00015	0.00486	CbGeAlD
Ziprasidone—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000145	0.00469	CbGeAlD
Ziprasidone—HTR7—liver—type 2 diabetes mellitus	0.000143	0.00465	CbGeAlD
Ziprasidone—HTR2A—kidney—type 2 diabetes mellitus	0.000142	0.00459	CbGeAlD
Ziprasidone—ADRA1A—liver—type 2 diabetes mellitus	0.000138	0.00449	CbGeAlD
Ziprasidone—ADRA2C—liver—type 2 diabetes mellitus	0.000132	0.00427	CbGeAlD
Ziprasidone—CYP3A4—kidney—type 2 diabetes mellitus	0.000131	0.00425	CbGeAlD
Ziprasidone—CYP2D6—kidney—type 2 diabetes mellitus	0.000129	0.00418	CbGeAlD
Ziprasidone—Clozapine—ADRA2A—type 2 diabetes mellitus	0.000116	0.0416	CrCbGaD
Ziprasidone—CYP1A2—liver—type 2 diabetes mellitus	0.000114	0.00371	CbGeAlD
Ziprasidone—CYP3A5—liver—type 2 diabetes mellitus	0.00011	0.00358	CbGeAlD
Ziprasidone—Clozapine—HTR2C—type 2 diabetes mellitus	0.000107	0.0383	CrCbGaD
Ziprasidone—Aripiprazole—CYP3A4—type 2 diabetes mellitus	9.92e-05	0.0356	CrCbGaD
Ziprasidone—Trazodone—CYP3A4—type 2 diabetes mellitus	9.87e-05	0.0354	CrCbGaD
Ziprasidone—HTR2A—liver—type 2 diabetes mellitus	8.95e-05	0.0029	CbGeAlD
Ziprasidone—Clozapine—CYP2E1—type 2 diabetes mellitus	8.47e-05	0.0304	CrCbGaD
Ziprasidone—CYP3A4—liver—type 2 diabetes mellitus	8.28e-05	0.00268	CbGeAlD
Ziprasidone—CYP2D6—liver—type 2 diabetes mellitus	8.15e-05	0.00264	CbGeAlD
Ziprasidone—Clozapine—CYP1A2—type 2 diabetes mellitus	8.06e-05	0.0289	CrCbGaD
Ziprasidone—Clozapine—CYP3A4—type 2 diabetes mellitus	5.33e-05	0.0191	CrCbGaD
Ziprasidone—Rash—Sitagliptin—type 2 diabetes mellitus	4.9e-05	0.000341	CcSEcCtD
Ziprasidone—Dermatitis—Sitagliptin—type 2 diabetes mellitus	4.9e-05	0.000341	CcSEcCtD
Ziprasidone—Headache—Glimepiride—type 2 diabetes mellitus	4.89e-05	0.00034	CcSEcCtD
Ziprasidone—Cough—Irbesartan—type 2 diabetes mellitus	4.88e-05	0.000339	CcSEcCtD
Ziprasidone—Headache—Sitagliptin—type 2 diabetes mellitus	4.87e-05	0.000339	CcSEcCtD
Ziprasidone—Anaemia—Losartan—type 2 diabetes mellitus	4.86e-05	0.000338	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	4.83e-05	0.000336	CcSEcCtD
Ziprasidone—Agitation—Losartan—type 2 diabetes mellitus	4.83e-05	0.000336	CcSEcCtD
Ziprasidone—Tinnitus—Ramipril—type 2 diabetes mellitus	4.83e-05	0.000336	CcSEcCtD
Ziprasidone—Hypertension—Irbesartan—type 2 diabetes mellitus	4.82e-05	0.000336	CcSEcCtD
Ziprasidone—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	4.81e-05	0.000335	CcSEcCtD
Ziprasidone—Angioedema—Losartan—type 2 diabetes mellitus	4.8e-05	0.000334	CcSEcCtD
Ziprasidone—Infection—Metformin—type 2 diabetes mellitus	4.8e-05	0.000334	CcSEcCtD
Ziprasidone—Insomnia—Valsartan—type 2 diabetes mellitus	4.8e-05	0.000334	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	4.78e-05	0.000332	CcSEcCtD
Ziprasidone—Paraesthesia—Valsartan—type 2 diabetes mellitus	4.76e-05	0.000331	CcSEcCtD
Ziprasidone—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	4.76e-05	0.000331	CcSEcCtD
Ziprasidone—Arthralgia—Irbesartan—type 2 diabetes mellitus	4.76e-05	0.000331	CcSEcCtD
Ziprasidone—Chest pain—Irbesartan—type 2 diabetes mellitus	4.76e-05	0.000331	CcSEcCtD
Ziprasidone—Myalgia—Irbesartan—type 2 diabetes mellitus	4.76e-05	0.000331	CcSEcCtD
Ziprasidone—Shock—Metformin—type 2 diabetes mellitus	4.75e-05	0.000331	CcSEcCtD
Ziprasidone—Insomnia—Orlistat—type 2 diabetes mellitus	4.74e-05	0.00033	CcSEcCtD
Ziprasidone—Anxiety—Irbesartan—type 2 diabetes mellitus	4.74e-05	0.00033	CcSEcCtD
Ziprasidone—Hypersensitivity—Glyburide—type 2 diabetes mellitus	4.74e-05	0.00033	CcSEcCtD
Ziprasidone—Nervous system disorder—Metformin—type 2 diabetes mellitus	4.74e-05	0.00033	CcSEcCtD
Ziprasidone—Thrombocytopenia—Metformin—type 2 diabetes mellitus	4.73e-05	0.000329	CcSEcCtD
Ziprasidone—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.73e-05	0.000329	CcSEcCtD
Ziprasidone—Vertigo—Losartan—type 2 diabetes mellitus	4.72e-05	0.000329	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	4.72e-05	0.000329	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4.72e-05	0.000328	CcSEcCtD
Ziprasidone—Somnolence—Valsartan—type 2 diabetes mellitus	4.72e-05	0.000328	CcSEcCtD
Ziprasidone—Syncope—Losartan—type 2 diabetes mellitus	4.72e-05	0.000328	CcSEcCtD
Ziprasidone—Paraesthesia—Orlistat—type 2 diabetes mellitus	4.71e-05	0.000327	CcSEcCtD
Ziprasidone—Leukopenia—Losartan—type 2 diabetes mellitus	4.71e-05	0.000327	CcSEcCtD
Ziprasidone—Skin disorder—Metformin—type 2 diabetes mellitus	4.69e-05	0.000326	CcSEcCtD
Ziprasidone—Immune system disorder—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000325	CcSEcCtD
Ziprasidone—Hyperhidrosis—Metformin—type 2 diabetes mellitus	4.67e-05	0.000325	CcSEcCtD
Ziprasidone—Dyspepsia—Valsartan—type 2 diabetes mellitus	4.67e-05	0.000325	CcSEcCtD
Ziprasidone—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	4.67e-05	0.000325	CcSEcCtD
Ziprasidone—Dizziness—Bromocriptine—type 2 diabetes mellitus	4.65e-05	0.000324	CcSEcCtD
Ziprasidone—Dry mouth—Irbesartan—type 2 diabetes mellitus	4.65e-05	0.000324	CcSEcCtD
Ziprasidone—Palpitations—Losartan—type 2 diabetes mellitus	4.65e-05	0.000323	CcSEcCtD
Ziprasidone—Nausea—Glimepiride—type 2 diabetes mellitus	4.63e-05	0.000322	CcSEcCtD
Ziprasidone—Arrhythmia—Ramipril—type 2 diabetes mellitus	4.63e-05	0.000322	CcSEcCtD
Ziprasidone—Loss of consciousness—Losartan—type 2 diabetes mellitus	4.62e-05	0.000321	CcSEcCtD
Ziprasidone—Nausea—Sitagliptin—type 2 diabetes mellitus	4.62e-05	0.000321	CcSEcCtD
Ziprasidone—Dyspepsia—Orlistat—type 2 diabetes mellitus	4.62e-05	0.000321	CcSEcCtD
Ziprasidone—Asthenia—Glyburide—type 2 diabetes mellitus	4.61e-05	0.000321	CcSEcCtD
Ziprasidone—Decreased appetite—Valsartan—type 2 diabetes mellitus	4.61e-05	0.000321	CcSEcCtD
Ziprasidone—Anorexia—Metformin—type 2 diabetes mellitus	4.61e-05	0.00032	CcSEcCtD
Ziprasidone—Cough—Losartan—type 2 diabetes mellitus	4.59e-05	0.000319	CcSEcCtD
Ziprasidone—Urticaria—Gliclazide—type 2 diabetes mellitus	4.59e-05	0.000319	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	4.58e-05	0.000319	CcSEcCtD
Ziprasidone—Alopecia—Ramipril—type 2 diabetes mellitus	4.58e-05	0.000318	CcSEcCtD
Ziprasidone—Fatigue—Valsartan—type 2 diabetes mellitus	4.57e-05	0.000318	CcSEcCtD
Ziprasidone—Abdominal pain—Gliclazide—type 2 diabetes mellitus	4.57e-05	0.000318	CcSEcCtD
Ziprasidone—Body temperature increased—Gliclazide—type 2 diabetes mellitus	4.57e-05	0.000318	CcSEcCtD
Ziprasidone—Decreased appetite—Orlistat—type 2 diabetes mellitus	4.56e-05	0.000317	CcSEcCtD
Ziprasidone—Mental disorder—Ramipril—type 2 diabetes mellitus	4.54e-05	0.000316	CcSEcCtD
Ziprasidone—Constipation—Valsartan—type 2 diabetes mellitus	4.54e-05	0.000316	CcSEcCtD
Ziprasidone—Infection—Irbesartan—type 2 diabetes mellitus	4.53e-05	0.000315	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	4.53e-05	0.000315	CcSEcCtD
Ziprasidone—Fatigue—Orlistat—type 2 diabetes mellitus	4.52e-05	0.000314	CcSEcCtD
Ziprasidone—Hypotension—Metformin—type 2 diabetes mellitus	4.52e-05	0.000314	CcSEcCtD
Ziprasidone—Erythema—Ramipril—type 2 diabetes mellitus	4.51e-05	0.000314	CcSEcCtD
Ziprasidone—Malnutrition—Ramipril—type 2 diabetes mellitus	4.51e-05	0.000314	CcSEcCtD
Ziprasidone—Shock—Irbesartan—type 2 diabetes mellitus	4.49e-05	0.000312	CcSEcCtD
Ziprasidone—Chest pain—Losartan—type 2 diabetes mellitus	4.48e-05	0.000311	CcSEcCtD
Ziprasidone—Myalgia—Losartan—type 2 diabetes mellitus	4.48e-05	0.000311	CcSEcCtD
Ziprasidone—Arthralgia—Losartan—type 2 diabetes mellitus	4.48e-05	0.000311	CcSEcCtD
Ziprasidone—Vomiting—Bromocriptine—type 2 diabetes mellitus	4.47e-05	0.000311	CcSEcCtD
Ziprasidone—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	4.47e-05	0.000311	CcSEcCtD
Ziprasidone—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	4.46e-05	0.000311	CcSEcCtD
Ziprasidone—Anxiety—Losartan—type 2 diabetes mellitus	4.46e-05	0.00031	CcSEcCtD
Ziprasidone—Tachycardia—Irbesartan—type 2 diabetes mellitus	4.45e-05	0.00031	CcSEcCtD
Ziprasidone—Rash—Bromocriptine—type 2 diabetes mellitus	4.44e-05	0.000309	CcSEcCtD
Ziprasidone—Dermatitis—Bromocriptine—type 2 diabetes mellitus	4.43e-05	0.000308	CcSEcCtD
Ziprasidone—Skin disorder—Irbesartan—type 2 diabetes mellitus	4.43e-05	0.000308	CcSEcCtD
Ziprasidone—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	4.41e-05	0.000307	CcSEcCtD
Ziprasidone—Headache—Bromocriptine—type 2 diabetes mellitus	4.41e-05	0.000307	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	4.4e-05	0.000306	CcSEcCtD
Ziprasidone—Diarrhoea—Glyburide—type 2 diabetes mellitus	4.4e-05	0.000306	CcSEcCtD
Ziprasidone—Dry mouth—Losartan—type 2 diabetes mellitus	4.38e-05	0.000305	CcSEcCtD
Ziprasidone—Anorexia—Irbesartan—type 2 diabetes mellitus	4.35e-05	0.000302	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	4.34e-05	0.000302	CcSEcCtD
Ziprasidone—Paraesthesia—Metformin—type 2 diabetes mellitus	4.34e-05	0.000302	CcSEcCtD
Ziprasidone—Muscle spasms—Ramipril—type 2 diabetes mellitus	4.33e-05	0.000301	CcSEcCtD
Ziprasidone—Confusional state—Losartan—type 2 diabetes mellitus	4.33e-05	0.000301	CcSEcCtD
Ziprasidone—Feeling abnormal—Orlistat—type 2 diabetes mellitus	4.32e-05	0.000301	CcSEcCtD
Ziprasidone—Dyspnoea—Metformin—type 2 diabetes mellitus	4.31e-05	0.0003	CcSEcCtD
Ziprasidone—Somnolence—Metformin—type 2 diabetes mellitus	4.3e-05	0.000299	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	4.29e-05	0.000298	CcSEcCtD
Ziprasidone—Infection—Losartan—type 2 diabetes mellitus	4.26e-05	0.000297	CcSEcCtD
Ziprasidone—Hypotension—Irbesartan—type 2 diabetes mellitus	4.26e-05	0.000296	CcSEcCtD
Ziprasidone—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	4.25e-05	0.000296	CcSEcCtD
Ziprasidone—Dyspepsia—Metformin—type 2 diabetes mellitus	4.25e-05	0.000296	CcSEcCtD
Ziprasidone—Tremor—Ramipril—type 2 diabetes mellitus	4.22e-05	0.000294	CcSEcCtD
Ziprasidone—Shock—Losartan—type 2 diabetes mellitus	4.22e-05	0.000294	CcSEcCtD
Ziprasidone—Urticaria—Valsartan—type 2 diabetes mellitus	4.22e-05	0.000293	CcSEcCtD
Ziprasidone—Nervous system disorder—Losartan—type 2 diabetes mellitus	4.21e-05	0.000293	CcSEcCtD
Ziprasidone—Thrombocytopenia—Losartan—type 2 diabetes mellitus	4.2e-05	0.000292	CcSEcCtD
Ziprasidone—Decreased appetite—Metformin—type 2 diabetes mellitus	4.2e-05	0.000292	CcSEcCtD
Ziprasidone—Abdominal pain—Valsartan—type 2 diabetes mellitus	4.19e-05	0.000292	CcSEcCtD
Ziprasidone—Tachycardia—Losartan—type 2 diabetes mellitus	4.19e-05	0.000291	CcSEcCtD
Ziprasidone—Nausea—Bromocriptine—type 2 diabetes mellitus	4.18e-05	0.000291	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	4.17e-05	0.00029	CcSEcCtD
Ziprasidone—Fatigue—Metformin—type 2 diabetes mellitus	4.17e-05	0.00029	CcSEcCtD
Ziprasidone—Urticaria—Orlistat—type 2 diabetes mellitus	4.17e-05	0.00029	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	4.15e-05	0.000289	CcSEcCtD
Ziprasidone—Hyperhidrosis—Losartan—type 2 diabetes mellitus	4.15e-05	0.000289	CcSEcCtD
Ziprasidone—Body temperature increased—Orlistat—type 2 diabetes mellitus	4.14e-05	0.000288	CcSEcCtD
Ziprasidone—Abdominal pain—Orlistat—type 2 diabetes mellitus	4.14e-05	0.000288	CcSEcCtD
Ziprasidone—Asthenia—Gliclazide—type 2 diabetes mellitus	4.14e-05	0.000288	CcSEcCtD
Ziprasidone—Agitation—Ramipril—type 2 diabetes mellitus	4.14e-05	0.000288	CcSEcCtD
Ziprasidone—Constipation—Metformin—type 2 diabetes mellitus	4.13e-05	0.000287	CcSEcCtD
Ziprasidone—Angioedema—Ramipril—type 2 diabetes mellitus	4.12e-05	0.000287	CcSEcCtD
Ziprasidone—Paraesthesia—Irbesartan—type 2 diabetes mellitus	4.09e-05	0.000285	CcSEcCtD
Ziprasidone—Anorexia—Losartan—type 2 diabetes mellitus	4.09e-05	0.000285	CcSEcCtD
Ziprasidone—Vomiting—Glyburide—type 2 diabetes mellitus	4.09e-05	0.000284	CcSEcCtD
Ziprasidone—Dyspnoea—Irbesartan—type 2 diabetes mellitus	4.07e-05	0.000283	CcSEcCtD
Ziprasidone—Rash—Glyburide—type 2 diabetes mellitus	4.06e-05	0.000282	CcSEcCtD
Ziprasidone—Somnolence—Irbesartan—type 2 diabetes mellitus	4.05e-05	0.000282	CcSEcCtD
Ziprasidone—Dermatitis—Glyburide—type 2 diabetes mellitus	4.05e-05	0.000282	CcSEcCtD
Ziprasidone—Vertigo—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000282	CcSEcCtD
Ziprasidone—Syncope—Ramipril—type 2 diabetes mellitus	4.04e-05	0.000281	CcSEcCtD
Ziprasidone—Leukopenia—Ramipril—type 2 diabetes mellitus	4.04e-05	0.000281	CcSEcCtD
Ziprasidone—Headache—Glyburide—type 2 diabetes mellitus	4.03e-05	0.00028	CcSEcCtD
Ziprasidone—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.01e-05	0.000279	CcSEcCtD
Ziprasidone—Hypotension—Losartan—type 2 diabetes mellitus	4.01e-05	0.000279	CcSEcCtD
Ziprasidone—Palpitations—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000277	CcSEcCtD
Ziprasidone—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.98e-05	0.000277	CcSEcCtD
Ziprasidone—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.96e-05	0.000276	CcSEcCtD
Ziprasidone—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.96e-05	0.000276	CcSEcCtD
Ziprasidone—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.95e-05	0.000275	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.95e-05	0.000275	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.94e-05	0.000274	CcSEcCtD
Ziprasidone—Cough—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000274	CcSEcCtD
Ziprasidone—Fatigue—Irbesartan—type 2 diabetes mellitus	3.93e-05	0.000273	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.91e-05	0.000272	CcSEcCtD
Ziprasidone—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.91e-05	0.000272	CcSEcCtD
Ziprasidone—Constipation—Irbesartan—type 2 diabetes mellitus	3.9e-05	0.000271	CcSEcCtD
Ziprasidone—Insomnia—Losartan—type 2 diabetes mellitus	3.88e-05	0.00027	CcSEcCtD
Ziprasidone—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.86e-05	0.000269	CcSEcCtD
Ziprasidone—Paraesthesia—Losartan—type 2 diabetes mellitus	3.85e-05	0.000268	CcSEcCtD
Ziprasidone—Urticaria—Metformin—type 2 diabetes mellitus	3.84e-05	0.000267	CcSEcCtD
Ziprasidone—Arthralgia—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000267	CcSEcCtD
Ziprasidone—Chest pain—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000267	CcSEcCtD
Ziprasidone—Myalgia—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000267	CcSEcCtD
Ziprasidone—Dyspnoea—Losartan—type 2 diabetes mellitus	3.83e-05	0.000266	CcSEcCtD
Ziprasidone—Anxiety—Ramipril—type 2 diabetes mellitus	3.83e-05	0.000266	CcSEcCtD
Ziprasidone—Nausea—Glyburide—type 2 diabetes mellitus	3.82e-05	0.000266	CcSEcCtD
Ziprasidone—Abdominal pain—Metformin—type 2 diabetes mellitus	3.82e-05	0.000266	CcSEcCtD
Ziprasidone—Dizziness—Gliclazide—type 2 diabetes mellitus	3.82e-05	0.000266	CcSEcCtD
Ziprasidone—Somnolence—Losartan—type 2 diabetes mellitus	3.81e-05	0.000265	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000265	CcSEcCtD
Ziprasidone—Asthenia—Valsartan—type 2 diabetes mellitus	3.81e-05	0.000265	CcSEcCtD
Ziprasidone—Dyspepsia—Losartan—type 2 diabetes mellitus	3.78e-05	0.000263	CcSEcCtD
Ziprasidone—Asthenia—Orlistat—type 2 diabetes mellitus	3.76e-05	0.000262	CcSEcCtD
Ziprasidone—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.76e-05	0.000261	CcSEcCtD
Ziprasidone—Dry mouth—Ramipril—type 2 diabetes mellitus	3.75e-05	0.000261	CcSEcCtD
Ziprasidone—Decreased appetite—Losartan—type 2 diabetes mellitus	3.73e-05	0.000259	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.73e-05	0.000259	CcSEcCtD
Ziprasidone—Confusional state—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000258	CcSEcCtD
Ziprasidone—Fatigue—Losartan—type 2 diabetes mellitus	3.7e-05	0.000257	CcSEcCtD
Ziprasidone—Vomiting—Gliclazide—type 2 diabetes mellitus	3.67e-05	0.000255	CcSEcCtD
Ziprasidone—Constipation—Losartan—type 2 diabetes mellitus	3.67e-05	0.000255	CcSEcCtD
Ziprasidone—Rash—Gliclazide—type 2 diabetes mellitus	3.64e-05	0.000253	CcSEcCtD
Ziprasidone—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.64e-05	0.000253	CcSEcCtD
Ziprasidone—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.63e-05	0.000253	CcSEcCtD
Ziprasidone—Urticaria—Irbesartan—type 2 diabetes mellitus	3.62e-05	0.000252	CcSEcCtD
Ziprasidone—Shock—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000252	CcSEcCtD
Ziprasidone—Headache—Gliclazide—type 2 diabetes mellitus	3.62e-05	0.000252	CcSEcCtD
Ziprasidone—Nervous system disorder—Ramipril—type 2 diabetes mellitus	3.61e-05	0.000251	CcSEcCtD
Ziprasidone—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.000251	CcSEcCtD
Ziprasidone—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.000251	CcSEcCtD
Ziprasidone—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.6e-05	0.000251	CcSEcCtD
Ziprasidone—Tachycardia—Ramipril—type 2 diabetes mellitus	3.59e-05	0.00025	CcSEcCtD
Ziprasidone—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.59e-05	0.00025	CcSEcCtD
Ziprasidone—Skin disorder—Ramipril—type 2 diabetes mellitus	3.57e-05	0.000249	CcSEcCtD
Ziprasidone—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.56e-05	0.000247	CcSEcCtD
Ziprasidone—Feeling abnormal—Losartan—type 2 diabetes mellitus	3.54e-05	0.000246	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	3.51e-05	0.000244	CcSEcCtD
Ziprasidone—Dizziness—Valsartan—type 2 diabetes mellitus	3.51e-05	0.000244	CcSEcCtD
Ziprasidone—Anorexia—Ramipril—type 2 diabetes mellitus	3.51e-05	0.000244	CcSEcCtD
Ziprasidone—Dizziness—Orlistat—type 2 diabetes mellitus	3.47e-05	0.000241	CcSEcCtD
Ziprasidone—Asthenia—Metformin—type 2 diabetes mellitus	3.47e-05	0.000241	CcSEcCtD
Ziprasidone—Hypotension—Ramipril—type 2 diabetes mellitus	3.44e-05	0.000239	CcSEcCtD
Ziprasidone—Nausea—Gliclazide—type 2 diabetes mellitus	3.43e-05	0.000239	CcSEcCtD
Ziprasidone—Urticaria—Losartan—type 2 diabetes mellitus	3.41e-05	0.000237	CcSEcCtD
Ziprasidone—Body temperature increased—Losartan—type 2 diabetes mellitus	3.39e-05	0.000236	CcSEcCtD
Ziprasidone—Abdominal pain—Losartan—type 2 diabetes mellitus	3.39e-05	0.000236	CcSEcCtD
Ziprasidone—Vomiting—Valsartan—type 2 diabetes mellitus	3.37e-05	0.000235	CcSEcCtD
Ziprasidone—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	3.36e-05	0.000234	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	3.35e-05	0.000233	CcSEcCtD
Ziprasidone—Rash—Valsartan—type 2 diabetes mellitus	3.35e-05	0.000233	CcSEcCtD
Ziprasidone—Dermatitis—Valsartan—type 2 diabetes mellitus	3.34e-05	0.000232	CcSEcCtD
Ziprasidone—Vomiting—Orlistat—type 2 diabetes mellitus	3.33e-05	0.000232	CcSEcCtD
Ziprasidone—Insomnia—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000231	CcSEcCtD
Ziprasidone—Headache—Valsartan—type 2 diabetes mellitus	3.32e-05	0.000231	CcSEcCtD
Ziprasidone—Diarrhoea—Metformin—type 2 diabetes mellitus	3.31e-05	0.00023	CcSEcCtD
Ziprasidone—Rash—Orlistat—type 2 diabetes mellitus	3.31e-05	0.00023	CcSEcCtD
Ziprasidone—Paraesthesia—Ramipril—type 2 diabetes mellitus	3.3e-05	0.00023	CcSEcCtD
Ziprasidone—Dermatitis—Orlistat—type 2 diabetes mellitus	3.3e-05	0.00023	CcSEcCtD
Ziprasidone—Headache—Orlistat—type 2 diabetes mellitus	3.28e-05	0.000228	CcSEcCtD
Ziprasidone—Dyspnoea—Ramipril—type 2 diabetes mellitus	3.28e-05	0.000228	CcSEcCtD
Ziprasidone—Asthenia—Irbesartan—type 2 diabetes mellitus	3.27e-05	0.000228	CcSEcCtD
Ziprasidone—Somnolence—Ramipril—type 2 diabetes mellitus	3.27e-05	0.000228	CcSEcCtD
Ziprasidone—Dyspepsia—Ramipril—type 2 diabetes mellitus	3.24e-05	0.000225	CcSEcCtD
Ziprasidone—Decreased appetite—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000222	CcSEcCtD
Ziprasidone—Dizziness—Metformin—type 2 diabetes mellitus	3.2e-05	0.000222	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.18e-05	0.000221	CcSEcCtD
Ziprasidone—Fatigue—Ramipril—type 2 diabetes mellitus	3.17e-05	0.000221	CcSEcCtD
Ziprasidone—Hypersensitivity—Losartan—type 2 diabetes mellitus	3.16e-05	0.00022	CcSEcCtD
Ziprasidone—Nausea—Valsartan—type 2 diabetes mellitus	3.15e-05	0.000219	CcSEcCtD
Ziprasidone—Constipation—Ramipril—type 2 diabetes mellitus	3.15e-05	0.000219	CcSEcCtD
Ziprasidone—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.12e-05	0.000217	CcSEcCtD
Ziprasidone—Nausea—Orlistat—type 2 diabetes mellitus	3.11e-05	0.000217	CcSEcCtD
Ziprasidone—Asthenia—Losartan—type 2 diabetes mellitus	3.08e-05	0.000214	CcSEcCtD
Ziprasidone—Vomiting—Metformin—type 2 diabetes mellitus	3.07e-05	0.000214	CcSEcCtD
Ziprasidone—Rash—Metformin—type 2 diabetes mellitus	3.05e-05	0.000212	CcSEcCtD
Ziprasidone—Dermatitis—Metformin—type 2 diabetes mellitus	3.04e-05	0.000212	CcSEcCtD
Ziprasidone—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.03e-05	0.000211	CcSEcCtD
Ziprasidone—Headache—Metformin—type 2 diabetes mellitus	3.03e-05	0.000211	CcSEcCtD
Ziprasidone—Dizziness—Irbesartan—type 2 diabetes mellitus	3.02e-05	0.00021	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.01e-05	0.000209	CcSEcCtD
Ziprasidone—Diarrhoea—Losartan—type 2 diabetes mellitus	2.94e-05	0.000204	CcSEcCtD
Ziprasidone—Urticaria—Ramipril—type 2 diabetes mellitus	2.92e-05	0.000203	CcSEcCtD
Ziprasidone—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000202	CcSEcCtD
Ziprasidone—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000202	CcSEcCtD
Ziprasidone—Vomiting—Irbesartan—type 2 diabetes mellitus	2.9e-05	0.000202	CcSEcCtD
Ziprasidone—Rash—Irbesartan—type 2 diabetes mellitus	2.88e-05	0.0002	CcSEcCtD
Ziprasidone—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.87e-05	0.0002	CcSEcCtD
Ziprasidone—Nausea—Metformin—type 2 diabetes mellitus	2.87e-05	0.0002	CcSEcCtD
Ziprasidone—Headache—Irbesartan—type 2 diabetes mellitus	2.86e-05	0.000199	CcSEcCtD
Ziprasidone—Dizziness—Losartan—type 2 diabetes mellitus	2.84e-05	0.000197	CcSEcCtD
Ziprasidone—Vomiting—Losartan—type 2 diabetes mellitus	2.73e-05	0.00019	CcSEcCtD
Ziprasidone—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.71e-05	0.000189	CcSEcCtD
Ziprasidone—Nausea—Irbesartan—type 2 diabetes mellitus	2.71e-05	0.000188	CcSEcCtD
Ziprasidone—Rash—Losartan—type 2 diabetes mellitus	2.71e-05	0.000188	CcSEcCtD
Ziprasidone—Dermatitis—Losartan—type 2 diabetes mellitus	2.7e-05	0.000188	CcSEcCtD
Ziprasidone—Headache—Losartan—type 2 diabetes mellitus	2.69e-05	0.000187	CcSEcCtD
Ziprasidone—Asthenia—Ramipril—type 2 diabetes mellitus	2.64e-05	0.000184	CcSEcCtD
Ziprasidone—Nausea—Losartan—type 2 diabetes mellitus	2.55e-05	0.000177	CcSEcCtD
Ziprasidone—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.52e-05	0.000175	CcSEcCtD
Ziprasidone—Dizziness—Ramipril—type 2 diabetes mellitus	2.43e-05	0.000169	CcSEcCtD
Ziprasidone—Vomiting—Ramipril—type 2 diabetes mellitus	2.34e-05	0.000163	CcSEcCtD
Ziprasidone—Rash—Ramipril—type 2 diabetes mellitus	2.32e-05	0.000161	CcSEcCtD
Ziprasidone—Dermatitis—Ramipril—type 2 diabetes mellitus	2.32e-05	0.000161	CcSEcCtD
Ziprasidone—Headache—Ramipril—type 2 diabetes mellitus	2.31e-05	0.00016	CcSEcCtD
Ziprasidone—Nausea—Ramipril—type 2 diabetes mellitus	2.19e-05	0.000152	CcSEcCtD
Ziprasidone—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	1.05e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.04e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.04e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.04e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.04e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.03e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.03e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.03e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.03e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	1.03e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.03e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.02e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.02e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.02e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.02e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.02e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.02e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.01e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	1.01e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.01e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.01e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.01e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	1e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	1e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.99e-07	1.02e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.98e-07	1.01e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	9.93e-07	1.01e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.93e-07	1.01e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	9.9e-07	1.01e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.87e-07	1e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.84e-07	1e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.82e-07	9.98e-06	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	9.8e-07	9.96e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.78e-07	9.94e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.78e-07	9.94e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	9.76e-07	9.93e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.68e-07	9.84e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.66e-07	9.82e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	9.64e-07	9.8e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.63e-07	9.79e-06	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.56e-07	9.72e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.55e-07	9.71e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	9.53e-07	9.69e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.5e-07	9.66e-06	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.44e-07	9.59e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.4e-07	9.56e-06	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.38e-07	9.53e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.37e-07	9.52e-06	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.36e-07	9.51e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.28e-07	9.44e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.27e-07	9.42e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	9.25e-07	9.41e-06	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.25e-07	9.41e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.22e-07	9.37e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.21e-07	9.36e-06	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.21e-07	9.36e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	9.2e-07	9.35e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	9.2e-07	9.35e-06	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.19e-07	9.34e-06	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.16e-07	9.31e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	9.15e-07	9.3e-06	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.13e-07	9.28e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.12e-07	9.27e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.1e-07	9.25e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	9.08e-07	9.23e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.07e-07	9.22e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.06e-07	9.21e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.04e-07	9.19e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.04e-07	9.19e-06	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.04e-07	9.19e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.02e-07	9.16e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.01e-07	9.16e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.99e-07	9.13e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.96e-07	9.11e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.96e-07	9.1e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.93e-07	9.08e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.91e-07	9.06e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	8.9e-07	9.05e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.9e-07	9.05e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.87e-07	9.02e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	8.86e-07	9e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	8.79e-07	8.94e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	8.76e-07	8.91e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.76e-07	8.91e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	8.71e-07	8.86e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	8.71e-07	8.86e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	8.69e-07	8.83e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	8.67e-07	8.82e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.67e-07	8.81e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.67e-07	8.81e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	8.64e-07	8.79e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.62e-07	8.76e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	8.61e-07	8.76e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.6e-07	8.74e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.57e-07	8.72e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	8.56e-07	8.7e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.55e-07	8.69e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.53e-07	8.67e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.53e-07	8.67e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.52e-07	8.66e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	8.52e-07	8.66e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.51e-07	8.65e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.5e-07	8.64e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.48e-07	8.62e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.46e-07	8.6e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.46e-07	8.6e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.44e-07	8.58e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	8.38e-07	8.52e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.37e-07	8.51e-06	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	8.37e-07	8.51e-06	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—type 2 diabetes mellitus	8.36e-07	8.5e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.36e-07	8.5e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.35e-07	8.49e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.35e-07	8.49e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.34e-07	8.48e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.32e-07	8.45e-06	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	8.31e-07	8.45e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	8.31e-07	8.44e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.3e-07	8.44e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.29e-07	8.43e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.25e-07	8.38e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.22e-07	8.36e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.21e-07	8.35e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.19e-07	8.32e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.18e-07	8.32e-06	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	8.14e-07	8.27e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	8.08e-07	8.21e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	8.08e-07	8.21e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.06e-07	8.2e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.02e-07	8.15e-06	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—type 2 diabetes mellitus	8.01e-07	8.14e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	7.96e-07	8.1e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.96e-07	8.09e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	7.95e-07	8.08e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	7.93e-07	8.06e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	7.93e-07	8.06e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	7.91e-07	8.04e-06	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	7.9e-07	8.03e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	7.88e-07	8.01e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.87e-07	8e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.84e-07	7.97e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.83e-07	7.96e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	7.8e-07	7.93e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.8e-07	7.93e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	7.78e-07	7.91e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	7.76e-07	7.89e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.76e-07	7.89e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.74e-07	7.87e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	7.74e-07	7.87e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.72e-07	7.85e-06	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.72e-07	7.85e-06	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.72e-07	7.84e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.7e-07	7.83e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.68e-07	7.81e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.68e-07	7.8e-06	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.67e-07	7.79e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	7.62e-07	7.74e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	7.62e-07	7.74e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.61e-07	7.73e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.6e-07	7.73e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.58e-07	7.71e-06	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	7.56e-07	7.69e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	7.54e-07	7.66e-06	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.51e-07	7.63e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	7.5e-07	7.63e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	7.44e-07	7.56e-06	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.39e-07	7.51e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	7.36e-07	7.48e-06	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.29e-07	7.41e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	7.23e-07	7.35e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.22e-07	7.34e-06	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	7.21e-07	7.33e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	7.14e-07	7.26e-06	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	7.11e-07	7.23e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.11e-07	7.22e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.09e-07	7.21e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.08e-07	7.2e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.07e-07	7.18e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.04e-07	7.16e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.04e-07	7.16e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	7.01e-07	7.12e-06	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.98e-07	7.09e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.98e-07	7.09e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	6.97e-07	7.08e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.97e-07	7.08e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.96e-07	7.07e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.95e-07	7.07e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.93e-07	7.04e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.91e-07	7.02e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.84e-07	6.95e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.82e-07	6.93e-06	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	6.81e-07	6.93e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	6.79e-07	6.9e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	6.75e-07	6.86e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	6.67e-07	6.78e-06	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.65e-07	6.76e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	6.65e-07	6.76e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	6.62e-07	6.73e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	6.57e-07	6.68e-06	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.56e-07	6.67e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.46e-07	6.57e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	6.45e-07	6.56e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	6.45e-07	6.56e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	6.42e-07	6.53e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.34e-07	6.44e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.2e-07	6.3e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	6.17e-07	6.27e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	6e-07	6.1e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.92e-07	6.02e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	5.9e-07	6e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	5.9e-07	6e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	5.86e-07	5.95e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	5.79e-07	5.89e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.72e-07	5.81e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.69e-07	5.78e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	5.68e-07	5.77e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.53e-07	5.62e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.44e-07	5.53e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.44e-07	5.53e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	5.37e-07	5.46e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.35e-07	5.44e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.34e-07	5.43e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.33e-07	5.41e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	5.31e-07	5.4e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.26e-07	5.34e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.24e-07	5.33e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	5.21e-07	5.29e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.02e-07	5.1e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	4.98e-07	5.06e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	4.98e-07	5.06e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.94e-07	5.02e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.93e-07	5.01e-06	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	4.92e-07	5.01e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.91e-07	4.99e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.9e-07	4.98e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	4.87e-07	4.95e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.85e-07	4.93e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.84e-07	4.92e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	4.56e-07	4.63e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.49e-07	4.57e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	3.5e-07	3.56e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	2.97e-07	3.02e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.29e-07	2.33e-06	CbGpPWpGaD
